Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk / Aradigm link on insulin device:

This article was originally published in Clinica

Executive Summary

Novo Nordisk and Aradigm plan the joint development of a pulmonary insulin delivery system, based on Aradigm's AerX drug delivery system. The deal includes other glucose-regulatory compounds as well as two other, unnamed and unrelated therapeutics. Novo gains worldwide rights to any of the resulting products and Aradigm gains $9 million in upfront payments and equity investment, with a total of $50 million in possible milestone payments thereafter. Aradigm is based in Hayward, California.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts